Arkolith/Insider Trading/ZYME/Form 4

Moore Paul Andrew

Chief Scientific OfficerZymeworks Inc. (ZYME) · full profile →Form 4 · filed Jan 12, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$217K
Net Open-Market Flow
-$217K
Transactions
6
2 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 12, 2026Option exercise(M)18K—$058K
Jan 12, 2026Sell(S)10K$22.67$217K48K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 12, 2026Grant(A)47K—$047K
Jan 12, 2026Grant(A)66K—$066K
Jan 12, 2026Grant(A)70K—$070K
Jan 12, 2026Option exercise(M)18K—$035K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-010834) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML